9. International Conference on Emerging Technologies in Drug Discovery and Development (IAPC-9)
Shanghai, Novotel Hotel
September 23-25, 2024

organized by the International Association of Physical Chemists and co-organized by:

Peking University School of Pharmaceutical Sciences,  北京大学药学院

Shanghai Jiao Tong University College of Pharmaceutical Sciences, 上海交通大学药学院

Medicilon, 美迪西

TandemAI, 上海腾迈联新生物技术有限公司

The conference is aimed at providing a unique global forum where scientists working in different but closely related areas of pharmaceutical research, from drug discovery through to drug development, will meet in a relaxed atmosphere to discuss and rationalize their results and challenges.

 

    Co-organized by:   

IAPC logo4PUSPS SJTUP medicilon medicilonadmetlogo286x66

 

Read more....

Scientific program
Courses
Social events
Abstract submission
SCI journal publication
Other publishing options
Abstract submission
SCI journal publication
Other publishing options
Registration options
How to register
Key dates

Featured speakers

Klara Valko
Klara obtained her PhD at Semmerlweis University in Budapest. Since 1995 Klara has been working with the Physico-chemical Characterization Group at GSK. Now she is director of Bio-Mimetic Chromatography Consultancy providing data analysis, biomimetic HPLC method set up and measurements, in vivo drug distribution modelling and various courses to pharmaceutical companies and manufacturers of analytical equipment. Klara is also a honorary professor at University College London, where she has been teaching the Physchem/ADME module for the Drug Discovery. She has published over 100 papers that achieved over 3000 citations. She wrote a book on “Physicochemical and Biomimetic Properties in Drug Discovery; Chromatographic Techniques for lead optimization” published by Wiley in 2014.

Klara ValkoBiomimetic chromatography

Ao Zhang
Zhang Ao was born in Sichuan, China, in 1969. He received his B.S. degree in Chemistry in 1992 from Sichuan Normal College, now Xihua Normal University. He was awarded the M.S. degree in Organic Chemistry in 1995 from Nankai University. Then, he worked at the Shanghai Institute of Organic Chemistry for 2 years and joined the predoctoral program of the same Institute in 1997 under the supervision of Professor Biao Jiang. After he was awarded the Ph.D. diploma in Organic Chemistry in 2000, he joined Professor Alan P. Kozikowski's Drug Discovery Group at Georgetown University Medical Center as a Postdoctoral Fellow. In 2002, he joined Professor John L. Neumeyer's Medicinal Chemistry Program as a Research Investigator at McLean Hospital, Harvard Medical School. He was promoted to Instructor at Harvard Medical School in 2003 and Assistant Director of the Medicinal Chemistry Program at McLean Hospital in 2004. He was awarded Alfred Pope Young Investigator Award in 2004 and Adam Corneel Young Investigator Award in 2005 from Harvard Medical School. In 2006 he received the Hundred Talent Project award from the Chinese Academy of Sciences, and became the Professor of Medicinal Chemistry at Shanghai Institute of Materia Medica (SIMM). In 2011, he was awarded the Distinguished Young Investigator Award from Chinese Natural Science Foundation. His research interests include the design and synthesis of novel small molecules as structural and functional probes for the diagnosis and treatment of brain disorders and cancer by using the state-of-art medicinal chemistry strategy. He has authored or co-authored over 80 publications and 40 patents. Several drug candidates from his research group are now under preclinical studies.

Ao ZhangProfessor and Dean, Shanghai Jiao Tong University College of Pharmaceutical Sciences

Johan Gabrielsson
Professor of integrative pharmacology +20 years of industrial experience as Senior Principal Scientist in research areas such as CV & GI & CNS & Cancer & Biologics. Author of the textbooks 'Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications' 5th ed. (2016) and 'Quantitative Pharmacology: An Introduction to Integrative Pharmacokinetic-Phar­macodynamic Analysis' 1st ed. (2012). It has shown that the book has been very useful in basic and advanced PK courses, tox courses, courses in clin pharm, basic pharmacology courses, phys chem among chemistry, pharmacy and medical programs. Now, a free electronic copy of the 5th edition of Prof. Gabrirlsson’s book can be reached on the following links: https://www.certara.com/pharmacokinetic-and-pharmacodynamic-data-analysis-ebook/?tm_medium=organic_social&utm_source=linkedin.com&utm_campaign=gabrielsson-ebook or Pharmacokinetic and Pharmacodynamic Data Analysis, PK/PD Concepts and Applications | Certara

Johan GabrielssonProf. of integrative pharmacology, Sweden

Ning Jao
Ning Jiao received his Ph.D. degree (2004) with Prof. Shengming Ma at Shanghai Institute of Organic Chemistry (SIOC). He then spent 2004-2006 as an Alexander von Humboldt Postdoctoral Fellow with Prof. Manfred T. Reetz at Max Planck Institute für Kohlenforschung. In 2007, he joined the faculty at Peking University as an Associate Professor, and was promoted to Full Professor in 2010, and is currently the Yangtze-river scholars distinguished Professor at Peking University. His current research efforts are focused on: 1) New reagents and new synthetic methodologies development 2) Bioactive compounds modification and new structural library construction.; 3) The discovery of new drugs for the treatment of metabolic syndrome. He is a Fellow of the Royal Society of Chemistry, a Fellow of the Chinese Chemical Society, and Associate Editor of Chemical Science.

Ning JaoPh.D., Professor, School of Pharmaceutical Sciences, Peking University

Alex Avdeef
Alex Avdeef, PhD, is an AAPS Fellow, and the author of Absorption and Drug Development, Wiley, 2012. For over 40 years, he has been teaching, researching, & developing methods, instruments, & analysis software for measurement of ionization constants, solubility of practically-insoluble drugs, miniaturized dissolution, & permeability. His accomplishments in the development of instrumentation include several well-known instruments currently manufactured by leading companies in the instrument market (e.g., ORION960 Autochemistry System). He has over 120 technical publications in primary scientific journals & chapters in books, 6 patents. He founded in-ADME Research (USA) and co-founded pION INC (USA) in 1996 & Sirius Analytical (UK) in 1989.

Alex AvdeefCEO, in-ADME Research

Qiyue Hu
Beyang Therapeutics is an innovative biotech founded by a team of experienced drug hunters in April 2021. Using its proprietary ExCEED platforms, the goal is to build a DreamWorksTM-like organization for early drug discovery focusing on the ophthalmology and oncology disease areas. BT01001, a small molecule eye drop for Diabetic Retinopathy will be ready for IND application with FDA in the middle of 2024. BT01002, a PCC for AML, will be ready for IND filing by the end of 2024. After 12 years in Pfizer La Jolla labs in the United States, he came back to China in 2011. From 2011 to 2021, he has served as the head of the molecular informatics department and senior director of the Shanghai R&D Center for Hengrui Medicine. He has made important contributions to 9 clinical stage molecules, including four small molecules and five biologics. He was awarded Shanghai Pujiang Talent in 2013. His bachelor’s degree was from the School of Pharmacy of Beijing Medical University. He then obtained a master’s degree in organic chemistry from Georgia State University.

Qiyue HuPrincipal scientist, Merck, USA

Christel Bergström
Dr Bergström is Associate Professor in Pharmaceutics at Uppsala University where she is heading a research group focusing on delivery of poorly soluble compounds. She is in the steering committee of the Swedish Drug Delivery Forum where she also leads the Oral Drug Delivery Platform with drug delivery to the colon and intestinal absorption of biologics being in focus. Dr Bergström is the cofounder of Center of Pharmaceutical Informatics at Uppsala University (now UDOPP) She is a cofounder of the Nordic Pharma Network and an EXCO member of a recently awarded NordForsk grant for a Nordic University Hub within patient-oriented products. She is also an EXCO member of the Globalization Pharmaceutics Education Network. In 2017, she was elected Deputy Dean of collaboration (Medicine and Pharmacy) at Uppsala University.

Christel BergströmUppsala University

Xiaobao Yang
Dr. Xiaobao Yang is the Founder, Chairman and Chief Executive Officer at Gluetacs Therapeutics, and also serves as a corporate mentor at ShanghaiTech University. He has over 15 years’ experience in drug discovery and formulation optimization, with 10 years’experience in targeting protein degradation. Prior to founding Gluetacs, he worked at Shanghai Institute for Advanced Immunochemical Studies in ShanghaiTech University, where he served as assistant research fellow. Dr. Yang began his career with Glaxo Smith Kline as Scientist of Medicinal Chemistry and turned to Dongyue Pharma as CMC head. Dr. Yang obtained his Ph.D. in East China University of Science and Technology and Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. He also completed his post-doctoral studies in the Division of Chemical Biology and Medicinal Chemistry at the University of North Carolina at Chapel Hill and Icahn School of Medicine at Mount Sinai.

Xiaobao YangGluetacs Founder, Chairman and Chief Executive Officer

Annete Bauer-Brandl
Annette Bauer-Brandl is an accredited pharmacist with a doctoral degree in Pharmaceutics. Currently she is a Professor in Pharmaceutical Technology at University of Southern Denmark. She is a specialist in the fields of materials science and processing (Quality by Design). She is well known for her awarded Handbook on Formulation, Manufacturing and Quality Assurance of Solid Dosage Forms. She serves at the EDQM and the Danish Pharmacopoeia Committee. Currently her research interest focusses on prediction of oral bioavailability of drugs from formulations, especially of enabling formulations of poorly soluble drugs. Her group has invented a novel biomimetic membrane that allows permeation experiments under harsh conditions such as digestive processes. She published more than 300 scientific contributions.

Annete Bauer-BrandlUniversity of Southern Denmark

Godefridus J. Peters
Godefridus (Frits) J. Peters was appointed 1989 as head of the division of (Biochemical) Pharmacology, and was head of the Laboratory Medical Oncology from 2003-2017. He was appointed as associate-professor in 1992 and as full professor in 2003. The research of Prof. Peters is focused on translation of preclinical pharmacology of anticancer agents to the clinic. Prof Peters was involved in several Phase I and 2 studies of drugs now registered for treatment of cancer such as gemcitabine, pemetrexed, erlotinib, while “failed” clinical studies led to the development of successful drugs. Prof. Peters has authored/co-authored >450 refereed research papers and reviews.

Godefridus J. PetersVMuc Amsterdam, The Netherlands

Tonglei Li
Dr. Tonglei Li is Professor and Allen Chao Endowed Chair in the Department of Industrial and Molecular Pharmaceutics at Purdue University. He received BS and MS in Chemistry and Computational Chemistry from Nankai University, China. He obtained PhD in Pharmaceutics and MS in Computer Science from Purdue University. He joined the University of Kentucky faculty and became an Associate Professor before returning to his alma mater and holding his current title. His research interests include computational chemistry and mathematics, multiscale modeling and simulation, high-performance computing, and drug development. Over the last several years, Dr. Li has ventured into chemical data learning by pioneering manifold learning of quantum information of molecules, striving to solve challenging problems in molecular engineering and drug research. Dr. Li currently serves as Editor-in-Chief of Pharmaceutical Research.

Tonglei LiPurdue University, USA

Houfu Liu
Houfu Liu is currently Vice President, Clinical Pharmacology/DMPK at SciNeuro Therapeutics Inc. He received his B.S. degree in Biology from Fudan University and his Ph.D. in pharmacokinetics/pharmacology from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Before SciNeuro, he was a senior director of DMPK at RetroLead Biopharma and associate director of Pharmacokinetics, Dynamics, and Metabolism, Translational Medicine and Early Development at Sanofi. Before Sanofi, Dr. Liu was a principal scientist and team leader of Mechanistic Safety and Disposition in Platform Technology and Science, GlaxoSmithKline R&D China, where he managed a team to provide DMPK support for various neuroscience drug discovery programs during 2008-2017. He has over 10 years of scientific, management and project experience within the pharmaceutical industry covering drug discovery and development in clinical pharmacology and DMPK area. Dr. Liu is the author of around 20 peer-reviewed publications. His research interests include population PK/PD and PBPK modeling and simulation, DDI, xenobiotic transporters, blood-brain barrier penetration.

Houfu LiuVice President, Clinical Pharmacology/DMPK, SciNeuro Therapeutics Inc.

Likun Wang
Dr Likun Wang obtained his Ph.D. from National University of Singapore in year 2011, in the area of pharmaceutical technology. Dr Wang worked for Johnson & Johnson Pharmaceutical Research & Development (Beerse, Belgium site) in the area of Preformulation and high throughput Drug Product & Drug Substance screening between 2011 and 2015 as senior scientist and group leader. Dr Wang joined Jiangsu Hengrui Medicine Co., Ltd. in year 2015 as the first director of Hengrui Nanjing R&D center. Dr Wang successfully built Hengrui Nanjing R&D teams, platforms, drug product pipelines, with more than 20 patents filings in 3 years’ time. Dr Wang founded Nanjing HaiWei Pharmaceutical Technologies Co., Ltd. in 2018, focusing on developing cutting edge technologies and technical services in the following areas: solid state chemistry, enabling formulation for poorly water soluble drugs, drug permeation enhancement , compaction simulation, stability prediction, kinetics modelling.

Likun WangNanjing HaiWei Pharmaceutical Technologies Co., Ltd.

Xiaoqiang Xiang
Prof. Xiaoqiang Xiang is currently Director for Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University. He is also PI of Shanghai Technical service platform of pharmacometrics. He received his Ph.D. of clinical pharmacology in University of Helsinki. Before that, he had done clinical research of pharmacogenomics and pharmacokinetics with a focus on anticancer drugs in National cancer center Singapore and conducted preclinical DMPK studies of drug development in CombinatoRx Singapore. After he joined Fudan University in 2012, his research interest focused on PBPK modeling. He has been awarded 8 national or Shanghai research grants as PI. Until now, he has published 86 SCI-indexed papers including 6 ESI-highly cited papers. He is associate director of the Shanghai Society of Drug Metabolism & Pharmacokinetics. He was also invited to draft six technical guidance of pharmacometrics by National Medical Products Administration.

Xiaoqiang XiangProfessor, School of Pharmacy, Fudan University

Dafang Zhong
Dr. Zhong obtained his Ph.D. (1989) degree in Pharmaceutical Chemistry from the University of Bonn, Germany. From 1994-2005, he worked as a professor in Shenyang Pharmaceutical University. Since June 2005, he has led the Center for DMPK Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He has published more than 400 papers He is a member of Chinese Pharmacopeia Commission and drafted the Guidance for Bioavailability and Bioequivalence Studies for Drug Preparations as well as Guidelines for Bioanalytical Method Validation for Chinese Pharmacopeia 2015. He also severs as an editor for Biomedical Chromatography, Journal of Chromatography B, and Bioanalysis.

Dafang ZhongProfessor and PI

Ren Hongcan
PhD of DMPK; 15 years experience in the drug discovery and development; lead the DMPK group for small molecule or antibody drug discovery and development in GenFleet; published articles in Expert opinion on drug metabolism and toxicity, AAPS J, frontiers in pharmacology and etc. as first author and (or) corresponding author. Contributed in 4 approved tyrosine kinase inhibitors, including Fruquintinib, Surufatinib, Savolitinib, and GFH925 (IBI351).

Ren HongcanPh.D, GenFleet

Tatjana Verbić
Dr Tatjana Ž. Verbić is Associate Professor at the Department of Analytical Chemistry, University of Belgrade – Faculty of Chemistry (UB-FC) where she obtained BSc, MSc, and PhD degrees. She was research associate at University of Utah, Iowa State University, postdoctoral fellow at Budapest University of Technology and Economics, and Fulbright Visiting Scholar at St. John’s University, New York. Her research is focused on fundamental scientific studies of various types of chemical equilibria in biologically active molecules and physico-chemical compound profiling in drug discovery and development, as well as on properties and application of molecularly imprinted polymers (MIPs). She was the leader of bilateral scientific project between Hungarian Academy of Sciences and Serbian Academy of Sciences and Arts, and the participant of many national and international projects. She was the supervisor for 3 defended PhD and numerous MSc and BSc theses. Dr Verbić is member of the Sebian Chemical Society (member of the Supervisory board), the American Chemical Society, and the International Association of Physical Chemists. She was the Vice Dean of Education at UB-FC (2015-2018). Currently, she is the national coordinator for the Matura exam in chemistry, the head of UB-FC publishing center and the commettee for monitoring and improving the quality of teaching, and the Chair of the Nenad M. Kostić board for chemical sciences.

Tatjana VerbićUniversity of Belgrade, Serbia

Jingwu Kang
Dr. Jingwu Kang graduated from the Shaanxi Normal University in 1990. He obtained his Ph.D in analytical chemistry in 1997 in Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences. From 1997 to 2003 he worked as a post doctor at the State Key Laboratory of Oxo Synthesis, Lanzhou Institute of Chemical Physics, Department of Pharmaceutical & Pharmacological Sciences, Leuven University, Belgium, and the Institute of Organic Chemistry, Tubingen University Germany, respectively. In 2003, he joined the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences as a professor. Since 2015, he joins the State Key Laboratory of Life Organic Chemistry. His work mainly focuses on developing new methods for drug screening and target identification.

Jingwu KangProfessor, Shanghai Institute of Organic Chemistry, Chinese Academy of Science (CAS)

Hassan Karimi-Maleh
Hassan Karimi-Maleh works as a professor in the School of Resource and Environment, University of Electronics Science and Technology of China (UESTC). He is a highly cited researcher selected by Clarivate Analytics 2018 (cross-filed), 2019 (Agriculture field) and 2020 (cross-filed), 2021 (Chemistry and Agriculture, two categories in one year) and 2022 (Chemistry and Agriculture, two categories in one year) and Top 1% Scientists in Chemistry and Agriculture simultaneously in ISI Essential Science Indicators from 2014 until now. He has published more than 400 SCI research papers with more than 21800 citations and H-index 92 (according to WOS report) and 27200 citations and h-index 99 (according to Google Scholar). He works on editorial board of more than 20 international journals, such as Alexandria Engineering Journal (co-editor in editor ELSEVIER IF 6.626. He also works as an adjunct Professor at the University of Johannesburg, South Africa, Saveetha School of Engineering, Chennai, Inda and Quchan University of Technology, Quchan, Iran. He worked as a leader nanobiosensor group at Ton Duc Thang University, Vietnam 2019-2020. He published one book with Springer publisher and also one chapter book with the same publisher. Recently, he published a paper in Science journal. He was a plenary speaker at many conferences such as The 8th International Conference on Water Resource and Environment (WRE 2022), the 6th Postgraduate Colloquium for Environmental Research 2022, the 7th International Conference on Agricultural and Biological Science (abs) (2021) and etc. His main research interest includes the development of chemically modified sensors and biosensors using DNA and enzymes as biological recognition elements for food, biological, pharmaceutical and environmental compounds analysis and investigation of electrochemistry behavior of electroactive materials such as polymers, organic and inorganic compounds. Recently, he focused on the synthesis of nanomaterials and their application in drug delivery and energy storage fields. He has a big network that works in 3 different major entities Environmental research group, Energy research group and Sensor research group.

Hassan Karimi-MalehUniversity of Electronics Science and Technology of China (UESTC)

Weikang Tao
Dr. Weikang Tao has served as Corp VP and General Manager of Global R&D of Innovative Medicines in Qilu Pharmaceuticals since Sept. of 2022. From Feb. of 2014 to Sept. of 2022, he was in the role of Corp VP and CEO of R&D at Hengrui Medicine Co., Ltd. where he headed the R&D centers based in China and in the US to discover and develop innovative medicines ranging from small molecule drugs, therapeutic antibodies/peptides, antibody-drug conjugates and immune cell therapeutics for various indications. Under his leadership, the R&D teams delivered more than 50 novel molecular entities into clinical trials in China and abroad, among which eight drugs have been launched in China. Formerly, he worked at Merck & Co., Inc. as a senior research fellow and functional head for more than a decade, where he led a number of drug R&D projects, discovered and developed four drug candidates into clinical trials. Between 2012 and 2014, he took the position of the vice president of R&D at Shanghai Chempartner Co., Ltd, a publicly traded company at that time, taking charge of multiple collaborative projects with MNCs and biotech companies. Dr. Tao has published more than 60 peer-reviewed research papers in peer-reviewed premier scientific journals and he is an inventor of more than 220 issued or pending patents in drug R&D or biomedical research. He obtained a Ph.D. degree from the University of Medicine & Dentistry of New Jersey and completed post-doctoral research at Princeton University.

Weikang TaoQilu Pharmaceuticals

Kin Tam
Kin Tam holds a DPhil in Physical Chemistry from the University of Oxford. He is currently Associate Professor in Biomedical Sciences at University of Macau. Before moving back to Macau in 2013, he worked for AstraZeneca at UK, for 12 years, progressing from a senior scientist, through to the position of DMPK Design Leader. He contributed to a number of drug discovery projects in the areas of oncology and led the development of high-throughput physicochemical assays. Prior to joining AstraZeneca, he developed new instruments with Sirius Analytical Instruments, for 5 years and commercialized UV-based devices for pKa determination. His current research interests include the development of small molecule inhibitors targeting cancer metabolism and Alzheimer’s disease. He is a fellow of the Royal Society of Chemistry and has >100 publications (H-index 39, citations >5000; Google Scholar). He is the editor for the journal ADMET & DMPK.

Kin TamFaculty of Health Sciences, University of Macau

Conference

Emerging technologies in drug discovery and developments is annual conference taking place in alternate European/Eastern Asia regions
Learn more

Courses

One or two-day intensive courses designed for students and pharmaceutical researchers who wish to broaden their knowledge and advance in the career.
More details

Social events

Rich social events will provide relaxed atmosphere for getting togehter
More Details

Thanks to our amazing sponsors